Merck Sharp + Dohme Corp.

Schering Corporation

Cliff C Cheng

Gerald Wayne Shipps, Jr

Xiaohua Huang

Matthew Richards

M Arshad Siddiqui

Binyuan Sun

Hongbo Zeng

Panduranga Adulla Reddy

Thierry Olivier Fischmann

Lianyun Zhao

Jose S Duca

Timothy J Guzi

Yongqi Deng

Zhaoyang Meng

Shuyi Tang

Yang Nan

Duan Liu

Praveen K Tadikonda

Tzu Tshin Wong

Michael P Dwyer

Peter Orth

Abdelghani Achab

Johannes H Voigt

Kartik M Keertikar

Andrew J McRiner

Marc A Labroli

Luis E Torres

Mehul F Patel

Iwona Wrona

Amit K Mandal

Kyle Ann Soucy

Yinyan Zhao

Brian M Eklov

Cory S Poker

Abdelghani Abe Achab

Andrew Mcriner

Iwona E Wrona

Marc M Labroli

Cory Poker

Jr Gerald W Shipps

The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. 

Anilinopiperazine derivatives and methods of use thereof

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ('FABP') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I) 

Inhibitors of fatty acid binding protein (FABP)

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R, R, R, and Rare as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders. 

Fused Tricyclic Compounds as novel mTOR inhibitors

The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors

The present invention relates to novel Heterocyclic Ether or Thioether Derivatives, compositions comprising the Heterocyclic Ether or Thioether Derivatives, and methods for using the Heterocyclic Ether or Thioether Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.

Thiazole carboxamide derivatives and their use to treat cancer

The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. 

2-aminothiazole-4-carboxylic amides as protein kinase inhibitors

Growing community of inventors

Cambridge, MA, United States of America

Cliff C Cheng